ReviewJournal of cellular and molecular medicine
Alzheimer's disease beyond the genomic era: nuclear magnetic resonance (NMR) spectroscopy-based metabolomics.
Review in Journal of cellular and molecular medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 63 citations in OpenAlex.
- Maternal Plasma Metabolic Profile Demarcates a Role for Neuroinflammation in Non-Typical Development of Children.Metabolites · 2021Article
- Multi-Omics Approaches in Immunological Research.Frontiers in immunology · 2021Review
- Serum Metabolomics Profiling of Commercially Mixed Functional Foods-Effects in Beta-Amyloid Induced Rats Measured UsingNutrients · 2020Article
- Mitochondria in Alzheimer's disease and their potential role in Alzheimer's proteostasis.Experimental neurology · 2020Review
- Plasma Biomarkers: Potent Screeners of Alzheimer's Disease.American journal of Alzheimer's disease and other dementias · 2019Review
- An Exploratory Analysis of Potential New Biomarkers of Cognitive Function.The journals of gerontology. Series A, Biological sciences and medical sciences · 2019Article
- Precision pharmacology for Alzheimer's disease.Pharmacological research · 2018Review
- Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study.PLoS medicine · 2018Article
- Metabolomic Assessment of Acute Cholestatic Injuries Induced by Thioacetamide and by Bile Duct Ligation, and the Protective Effects of Huang-Lian-Jie-Du-Decoction.Frontiers in pharmacology · 2018Article
- Amyloid β42 peptide is toxic to non-neural cells inBiology open · 2017Article
- Early Effect of AmyloidBioMed research international · 2017Article
- Plasma metabolic profile delineates roles for neurodegeneration, pro-inflammatory damage and mitochondrial dysfunction in the FMR1 premutation.The Biochemical journal · 2016Article
- Metabolic changes may precede proteostatic dysfunction in a Drosophila model of amyloid beta peptide toxicity.Neurobiology of aging · 2016Article
- Plasma Biomarkers for Monitoring Brain Pathophysiology in FMR1 Premutation Carriers.Frontiers in molecular neuroscience · 2016Article
- Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer's disease.Translational psychiatry · 2015Article
- Recent advances in the application of metabolomics to Alzheimer's Disease.Biochimica et biophysica acta · 2014Review
- A review of β-amyloid neuroimaging in Alzheimer's disease.Frontiers in neuroscience · 2014Review
- Review: toxicometabolomics.Journal of applied toxicology : JAT · 2013Review
- Molecular signatures from omics data: from chaos to consensus.Biotechnology journal · 2012Review
- Detection of asymptomatic nigrostriatal dopaminergic lesion in rats by exhaled air analysis using carbon nanotube sensors.ACS chemical neuroscience · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a complex disease, with no definitive biomarkers available that allow clinical diagnosis; this represents a major problem for the advance of efficient drug discovery programs. A successful approach towards the understanding and treatment of AD should take into consideration this complex nature. In this sense, metabolic networks are subject to severe stoichiometric restrictions. Metabolomics amplifies changes both in the proteome and the genome, and represents a more accurate approximation to the phenotype of an organism in health and disease. In this article, we will examine the current rationale for metabolomics in AD, its basic methodology and the available data in animal models and human studies. The discussed topics will highlight the importance of being able to use the metabolomic information in order to understand disease mechanisms from a systems biology perspective as a non-invasive approach to diagnose and grade AD. This could allow the assessment of new therapies during clinical trials, the identification of patients at risk to develop adverse effects during treatment and the final implementation of new tools towards a more personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.